Welcome to our dedicated page for International Isotopes news (Ticker: INIS), a resource for investors and traders seeking the latest updates and insights on International Isotopes stock.
International Isotopes Inc. (INIS) delivers specialized radioisotope products and calibration standards for nuclear medicine and industrial applications. This page provides authorized news updates directly from the company and verified industry sources.
Access timely reports on product developments, financial performance, and regulatory milestones. Key updates include radiopharmaceutical innovations, cobalt recycling initiatives, and medical device advancements. Investors will find earnings releases, partnership announcements, and manufacturing updates critical for informed analysis.
All content is curated to meet investor and industry professional needs, focusing on operational developments without speculative commentary. Bookmark this page for streamlined tracking of INIS's progress in radiation therapy solutions and nuclear medicine standards.
International Isotopes (OTCQB: INIS) announced its fiscal Q1 2024 results, revealing a 6% decline in revenue to $2.90M from $3.09M in Q1 2023 due to global Cobalt-57 isotope shortages. Nonetheless, the Theranostics Products segment experienced an 8% revenue growth, and the Cobalt Products segment saw a 48% increase. Gross profit rose by 5% to $1.87M, while the net loss widened slightly to $154K from $148K in Q1 2023. Operating income also decreased by 80%. Cash and cash equivalents decreased to $2.37M from $2.69M at the end of 2023. Despite isotope constraints, the company anticipates growth in the Nuclear Medicine segment by late Q3 2024 and plans to commercialize new Medical Devices later this year.
International Isotopes Inc. reported a significant 16% increase in revenue for the fiscal year 2022, totaling
International Isotopes Inc. (OTCQB: INIS) reported a 9% revenue increase for the first nine months of 2022, totaling $8,031,522, compared to $7,369,922 in 2021. The company achieved a net profit of $414,328 year-to-date. However, the cost of sales rose by approximately 15%, and operating expenses increased by 19% primarily due to heightened R&D costs. Despite these challenges, the cash balance remains strong at $3,000,000. Management anticipates continued growth in various segments, including radiochemical products.
FAQ
What is the current stock price of International Isotopes (INIS)?
What is the market cap of International Isotopes (INIS)?
